$RNLXY
Renalytix plc Stock $rnlxy

$rnlxy Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000095017023050231 Filed on September 28, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$459.0K	$1.242M	$3.403M
YoY Change	-52.63%	-24.41%	14.58%
Cost Of Revenue	$502.0K	$1.292M	$2.683M
YoY Change	-27.87%	3.86%	28.01%
Gross Profit	-$43.00K	-$50.00K	$720.0K
YoY Change	-115.75%	-112.53%	-17.62%
Gross Profit Margin	-9.37%	-4.03%	21.16%
Selling, General & Admin		$20.70M	$34.46M
YoY Change		-32.86%	-26.02%
% of Gross Profit			4785.69%
Research & Development	$2.787M		$14.30M
YoY Change	-25.82%		-2.39%
% of Gross Profit			1985.83%
Depreciation & Amortization	$127.0K	$1.284M	$508.0K
YoY Change	-2.31%	-3.6%	3.89%
% of Gross Profit			70.56%
Operating Expenses	$8.846M	$20.70M	$42.94M
YoY Change	-26.25%	-32.86%	-20.56%
Operating Profit	-$8.889M	-$20.75M	-$42.22M
YoY Change	-24.17%	-31.81%	-20.61%
Interest Expense		-$3.211M	-$4.404M
YoY Change		-142.4%	127.83%
% of Operating Profit
Other Income/Expense, Net	$100.0K	$384.0K	$538.0K
YoY Change			-94.44%
Pretax Income	-$10.15M	-$23.57M	-$45.61M
YoY Change	-15.06%	3.16%	0.78%
Income Tax	$0.00	$3.000K	$2.000K
% Of Pretax Income
Net Earnings	-$10.15M	-$23.58M	-$45.61M
YoY Change	-15.05%	-30.14%	0.73%
Net Earnings / Revenue	-2212.2%	-1898.23%	-1340.2%
Basic Earnings Per Share	-$0.11		-$0.55
Diluted Earnings Per Share	-$0.11	-$0.26	-$0.55
COMMON SHARES
Basic Shares Outstanding	95.02M		82.21M
Diluted Shares Outstanding	94.77M		82.21M

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$26.27M	$26.27M
YoY Change		-40.58%	-40.58%
Cash & Equivalents	$13.90M	$24.68M
Short-Term Investments		$1.592M	$1.592M
Other Short-Term Assets		$566.0K	$566.0K
YoY Change		-50.87%	-50.87%
Inventory		$718.0K	$718.0K
Prepaid Expenses
Receivables	$1.014M	$776.0K	$776.0K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$16.47M	$26.88M	$28.33M
YoY Change		-39.93%	-40.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$944.0K	$1.027M	$1.221M
YoY Change		-59.85%	-29.14%
Goodwill
YoY Change
Intangibles	$974.0K	$1.050M
YoY Change		-11.69%
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets		$51.00K	$51.00K
YoY Change
Total Long-Term Assets	$3.069M	$3.747M	$13.78M
YoY Change		-29.45%	-12.91%
TOTAL ASSETS
Total Short-Term Assets	$16.47M	$26.88M	$28.33M
Total Long-Term Assets	$3.069M	$3.747M	$13.78M
Total Assets	$19.54M	$30.63M	$42.12M
YoY Change		-38.82%	-33.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$2.935M	$2.935M
YoY Change		113.3%	19.31%
Accrued Expenses	$4.566M	$6.644M	$8.578M
YoY Change		117.12%	77.93%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due		$4.619M	$4.619M
YoY Change		-0.88%	-0.88%
Total Short-Term Liabilities	$15.17M	$16.14M	$16.13M
YoY Change		37.02%	32.18%
LONG-TERM LIABILITIES
Long-Term Debt		$7.531M	$7.531M
YoY Change		-4.48%	-4.48%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$7.531M	$7.531M
YoY Change		-4.48%	-4.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.17M	$16.14M	$16.13M
Total Long-Term Liabilities		$7.531M	$7.531M
Total Liabilities	$21.03M	$23.66M	$23.66M
YoY Change		21.61%	17.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$188.5M	-$178.3M
YoY Change		34.36%
Common Stock	$188.3M	$186.7M
YoY Change		13.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.491M	$6.967M	$18.45M
YoY Change
Total Liabilities & Shareholders Equity	$19.54M	$30.63M	$42.12M
YoY Change		-38.82%	-33.42%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$10.15M	-$23.58M	-$45.61M
YoY Change	-15.05%	-30.14%	0.73%
Depreciation, Depletion And Amortization	$127.0K	$1.284M	$508.0K
YoY Change	-2.31%	-3.6%	3.89%
Cash From Operating Activities	-$9.504M	-$17.98M	-$34.09M
YoY Change	33.5%	-15.63%	-25.78%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities		$64.00K	$0.00
YoY Change
Cash From Investing Activities	$0.00	$64.00K	$0.00
YoY Change		-220.75%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$20.30M
YoY Change			130.53%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.065M	16.73M	16.39M
YoY Change	12.82%	-33.73%	-36.07%
NET CHANGE
Cash From Operating Activities	-9.504M	-17.98M	-34.09M
Cash From Investing Activities	0.000	64.00K	0.000
Cash From Financing Activities	-1.065M	16.73M	16.39M
Net Change In Cash	-10.79M	-1.185M	-16.65M
YoY Change	4.84%	-130.51%	-20.54%
FREE CASH FLOW
Cash From Operating Activities	-$9.504M	-$17.98M	-$34.09M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$17.98M	-$34.09M
YoY Change		-15.42%	-26.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001811115
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2023	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39387
CY2023	dei	Entity Registrant Name EntityRegistrantName	Renalytix plc
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Finsgate5-7 Cranwood Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2023	dei	Entity Address Country EntityAddressCountry	GB
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	EC1V 9EE
CY2023	dei	City Area Code CityAreaCode	20
CY2023	dei	Local Phone Number LocalPhoneNumber	3139 2910
CY2023	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.0025 per share
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2022Q4	dei	Entity Public Float EntityPublicFloat	44938090
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	95019440
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24682000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41333000
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	776000
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	901000
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1424000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2445000
CY2023Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0
CY2022Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	75000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	26882000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	44754000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1027000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1369000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	159000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2023Q2	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	1460000
CY2022Q2	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	2744000
CY2023Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	0
CY2022Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	9000
CY2023Q2	us-gaap	Other Assets OtherAssets	1101000
CY2022Q2	us-gaap	Other Assets OtherAssets	1189000
CY2023Q2	us-gaap	Assets Assets	30629000
CY2022Q2	us-gaap	Assets Assets	50065000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6644000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3060000
CY2023Q2	rnlx	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	1963000
CY2022Q2	rnlx	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	1496000
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	46000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	130000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4463000
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4660000
CY2023Q2	rnlx	Payable To Affiliate Current PayableToAffiliateCurrent	0
CY2022Q2	rnlx	Payable To Affiliate Current PayableToAffiliateCurrent	55000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16136000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11776000
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	7485000
CY2022Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	7682000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2023Q2	us-gaap	Liabilities Liabilities	23662000
CY2022Q2	us-gaap	Liabilities Liabilities	19458000
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0025
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0025
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	98750054
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	98750054
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93781478
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93781478
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74760432
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74760432
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	286000
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	228000
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	186456000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	164012000
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1450000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-915000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178325000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-132718000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6967000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	30607000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30629000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50065000
CY2023	us-gaap	Revenues Revenues	3403000
CY2022	us-gaap	Revenues Revenues	2970000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	2683000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	2096000
CY2023	us-gaap	Gross Profit GrossProfit	720000
CY2022	us-gaap	Gross Profit GrossProfit	874000
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14298000
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14648000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28662000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39524000
CY2023	rnlx	Performance Of Contract Liability To Affiliate PerformanceOfContractLiabilityToAffiliate	19000
CY2022	rnlx	Performance Of Contract Liability To Affiliate PerformanceOfContractLiabilityToAffiliate	115000
CY2023	us-gaap	Operating Expenses OperatingExpenses	42941000
CY2022	us-gaap	Operating Expenses OperatingExpenses	54057000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-42221000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-53183000
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-9000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	9000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	358000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	9694000
CY2023	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	1282000
CY2022	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	5900000
CY2023	rnlx	Fair Value Adjustment To Convertible Notes FairValueAdjustmentToConvertibleNotes	3107000
CY2022	rnlx	Fair Value Adjustment To Convertible Notes FairValueAdjustmentToConvertibleNotes	-3998000
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	656000
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	131000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45605000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45251000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-45607000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-45276000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82210050
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72861448
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82210050
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73837496
CY2023	rnlx	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	-337000
CY2022	rnlx	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	536000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-198000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9727000
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	46142000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	54467000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	71461000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	8586000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	209000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	197000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4621000
CY2022	rnlx	Changes In The Fair Value Of The Convertible Notes ChangesInTheFairValueOfTheConvertibleNotes	536000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9727000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-45276000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	30607000
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	19305000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	261000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2936000
CY2023	rnlx	Changes In The Fair Value Of The Convertible Notes ChangesInTheFairValueOfTheConvertibleNotes	-337000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-198000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-45607000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6967000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-45607000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-45276000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	508000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	489000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2932000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4621000
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-9000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	9000
CY2023	rnlx	Reversal Of Kantaro Liability ReversalOfKantaroLiability	55000
CY2022	rnlx	Reversal Of Kantaro Liability ReversalOfKantaroLiability	119000
CY2023	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	1282000
CY2022	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	5900000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1008000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	7340000
CY2023	rnlx	Fair Value Adjustments To Convertible Debt FairValueAdjustmentsToConvertibleDebt	1999000
CY2022	rnlx	Fair Value Adjustments To Convertible Debt FairValueAdjustmentsToConvertibleDebt	-3998000
CY2023	rnlx	Non Cash Lease Expense NonCashLeaseExpense	106000
CY2022	rnlx	Non Cash Lease Expense NonCashLeaseExpense	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-125000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	307000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1299000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1487000
CY2023	us-gaap	Increase Decrease In Due From Affiliates Current IncreaseDecreaseInDueFromAffiliatesCurrent	-75000
CY2022	us-gaap	Increase Decrease In Due From Affiliates Current IncreaseDecreaseInDueFromAffiliatesCurrent	-1000
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	80000
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1418000
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	368000
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	722000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3397000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1505000
CY2023	rnlx	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	451000
CY2022	rnlx	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	1271000
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-46000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-76000
CY2023	us-gaap	Increase Decrease In Due To Affiliates IncreaseDecreaseInDueToAffiliates	0
CY2022	us-gaap	Increase Decrease In Due To Affiliates IncreaseDecreaseInDueToAffiliates	-176000
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-53000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34085000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45924000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	557000
CY2023	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	0
CY2022	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	105000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-662000
CY2023	rnlx	Payment Of Convertible Notes Principal PaymentOfConvertibleNotesPrincipal	3180000
CY2022	rnlx	Payment Of Convertible Notes Principal PaymentOfConvertibleNotesPrincipal	0
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	18020000
CY2023	rnlx	Payments Of Debt Issuance Costs1 PaymentsOfDebtIssuanceCosts1	0
CY2022	rnlx	Payments Of Debt Issuance Costs1 PaymentsOfDebtIssuanceCosts1	1382000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20296000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8804000
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	991000
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	218000
CY2023	rnlx	Proceeds From The Issuance Of Ordinary Shares Under Employee Share Purchase Plan ProceedsFromTheIssuanceOfOrdinarySharesUnderEmployeeSharePurchasePlan	261000
CY2022	rnlx	Proceeds From The Issuance Of Ordinary Shares Under Employee Share Purchase Plan ProceedsFromTheIssuanceOfOrdinarySharesUnderEmployeeSharePurchasePlan	209000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	197000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16386000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25630000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1048000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2839000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16651000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23795000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41333000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	65128000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24682000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41333000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	265000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">1. Business and risks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Renalytix PLC and its wholly-owned subsidiaries, the “Company” or "Renalytix" is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and significantly lower healthcare costs. KidneyIntelX, the Company’s first-in-class diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from EHR systems, to generate a unique patient risk score. Additionally, the Company has successfully completed a statement of work with AstraZeneca Pharmaceuticals LP (“AstraZeneca”) to conduct a feasibility study to determine the impact of the use of the Company’s KidneyIntelX platform to optimize utilization of various CKD agents. As a result of the initial success with AstraZeneca the Company plans to pursue further collaborations with pharmaceutical companies and make ‘Pharmaceutical Services Revenue’ a core part of the business going forward with the goal of improving guideline-based standard-of-care for optimal utilization of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Since inception in March 2018, the Company has focused primarily on organizing and staffing the Company, raising capital, developing the KidneyIntelX platform, conducting clinical validation studies for KidneyIntelX, establishing and protecting its intellectual property portfolio and commercial laboratory operations, pursuing regulatory clearance and developing a reimbursement strategy. The Company has funded its operations primarily through equity and debt financings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the diagnostics industry, including, but not limited to, ability to secure additional capital to fund operations, compliance with governmental regulations, development by competitors of new technological innovations, dependence on key personnel and protection of proprietary technology. To achieve widespread usage, KidneyIntelX and additional diagnostic products currently under development will require extensive clinical testing and validation prior to regulatory approval and commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178300000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimate include the assumptions used in determining the fair value of share-based awards, determining the fair value of the bonds, recording the prepaid/accrual and associated expense for research and development activities performed for the Company by third parties and determining useful lives of property and equipment and capitalized software.</span></p>
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	100000
CY2023Q2	us-gaap	Cash Cash	24700000
CY2022Q2	us-gaap	Cash Cash	41300000
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	100000
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	0
CY2023	rnlx	Number Of Samples Collected NumberOfSamplesCollected	100
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	100000
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	46000
CY2021Q2	us-gaap	Deferred Revenue DeferredRevenue	122000
CY2023	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	0
CY2022	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	67000
CY2023	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	46000
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	143000
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	0
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	46000
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	12342000
CY2023	rnlx	Change Due To Payment Of Principal And Interest ChangeDueToPaymentOfPrincipalAndInterest	-4287000
CY2023	rnlx	Fair Value Adjustments FairValueAdjustments	3107000
CY2023	rnlx	Change In Credit Risk Associated With Fair Value ChangeInCreditRiskAssociatedWithFairValue	-337000
CY2023	rnlx	Fair Value Fx Impact FairValueFxImpact	1123000
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	11948000
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1877000
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.2508
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7.7924
CY2022Q2	rnlx	Repayment Of Deferred Amortization Percentage RepaymentOfDeferredAmortizationPercentage	1
CY2022Q3	rnlx	Amount Of Cash Amortization Payment AmountOfCashAmortizationPayment	1400000
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1878000
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	850000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	509000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1027000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1369000
CY2023	us-gaap	Depreciation Depreciation	300000
CY2022	us-gaap	Depreciation Depreciation	300000
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1526000
CY2022Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1476000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1526000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1476000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	476000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	287000
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1050000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1189000
CY2023Q2	us-gaap	Capitalized Software Development Costs For Software Sold To Customers CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers	1100000
CY2022Q2	us-gaap	Capitalized Software Development Costs For Software Sold To Customers CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers	1200000
CY2023	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	200000
CY2022	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	200000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	181000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	181000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	142000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	125000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	125000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	296000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1050000
CY2022Q3	rnlx	Principal Of Amount Of Cash Amortization PrincipalOfAmountOfCashAmortization	1100000
CY2022Q3	rnlx	Amount Of Cash Amortization Interest Payment AmountOfCashAmortizationInterestPayment	300000
CY2022Q4	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	300000
CY2023Q1	rnlx	Amount Of Cash Amortization Payment AmountOfCashAmortizationPayment	1400000
CY2023Q1	rnlx	Principal Of Amount Of Cash Amortization PrincipalOfAmountOfCashAmortization	1100000
CY2023Q1	rnlx	Amount Of Cash Amortization Interest Payment AmountOfCashAmortizationInterestPayment	300000
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	442000
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	551000
CY2023Q2	rnlx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	1657000
CY2022Q2	rnlx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	909000
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3866000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1437000
CY2023Q2	rnlx	Accrued License And Royalty Expense AccruedLicenseAndRoyaltyExpense	669000
CY2022Q2	rnlx	Accrued License And Royalty Expense AccruedLicenseAndRoyaltyExpense	151000
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6644000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3060000
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	21200000
CY2022Q2	rnlx	Senior Convertible Bond Par Value Percentage SeniorConvertibleBondParValuePercentage	0.85
CY2022Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	18000000
CY2022Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.055
CY2022Q2	rnlx	Debt Instrument Convertible Conversion Price Percentage DebtInstrumentConvertibleConversionPricePercentage	0.20
CY2022Q2	rnlx	Debt Instrument Reset Down Term1 DebtInstrumentResetDownTerm1	P12M
CY2022Q2	rnlx	Debt Instrument Reset Down Term2 DebtInstrumentResetDownTerm2	P24M
CY2022Q2	rnlx	Debt Instrument Reset Down Term3 DebtInstrumentResetDownTerm3	P36M
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7.25
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.2508
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	6.8757
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7.25
CY2023Q2	rnlx	Amount Of Cash Amortization Payment AmountOfCashAmortizationPayment	1400000
CY2023Q2	rnlx	Principal Of Amount Of Cash Amortization PrincipalOfAmountOfCashAmortization	1100000
CY2023Q2	rnlx	Amount Of Cash Amortization Interest Payment AmountOfCashAmortizationInterestPayment	300000
CY2023	rnlx	Principal Amount Outstanding Of Cash Amortization PrincipalAmountOutstandingOfCashAmortization	18000000
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	16900000
CY2022Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1400000
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	11900000
CY2023	rnlx	Incremental Borrowing Rate Of Average Commercial Real Estate Loans IncrementalBorrowingRateOfAverageCommercialRealEstateLoans	0.10
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	159000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	130000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41000
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	171000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	368000
CY2023	us-gaap	Lease Cost LeaseCost	688000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	129000
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M24D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	138000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	46000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	184000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13000
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	171000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	98750054
CY2023	us-gaap	Dividends Cash DividendsCash	0
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	20300000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2428688
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	3.626
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	8800000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2936000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4621000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.669
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.614
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.032
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.013
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4599899
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.06
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	571300
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.91
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	202623
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.86
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4968576
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4008293
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.39
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M12D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4968576
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2023Q2	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	256000
CY2022Q2	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	0
CY2023Q2	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction	55000
CY2022Q2	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction	0
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-712000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13061000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-44894000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-32194000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-45606000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-45255000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.205
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.19
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.104
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.037
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.014
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.312
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.241
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.011
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.026
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37740000
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27201000
CY2023Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2826000
CY2022Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2814000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3150000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1327000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1025000
CY2023Q2	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	0
CY2022Q2	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	0
CY2023Q2	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	0
CY2022Q2	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	0
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	964000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	311000
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	73000
CY2022Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45602000
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31113000
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	453000
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	578000
CY2023Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	386000
CY2022Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	473000
CY2023Q2	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0
CY2022Q2	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	89000
CY2023Q2	rnlx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	51000
CY2022Q2	rnlx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	0
CY2023	rnlx	Deferred Tax Liabilities Unrealized Currency Losses DeferredTaxLiabilitiesUnrealizedCurrencyLosses	-16000
CY2022	rnlx	Deferred Tax Liabilities Unrealized Currency Losses DeferredTaxLiabilitiesUnrealizedCurrencyLosses	-16000
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	453000
CY2022Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	578000
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	rnlx	Threshold Percentage Set Off Of Annual Profits By Operating Loss Carry Forward ThresholdPercentageSetOffOfAnnualProfitsByOperatingLossCarryForward	0.80
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14500000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10100000
CY2023	rnlx	Net Operating Loss Description NetOperatingLossDescription	In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of 5-percent shareholders in the stock of a corporation by more than 50 percentage points over a three-year period.
CY2023Q2	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P5Y
CY2023	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0
CY2023	rnlx	Gain From Loan Prior To Repayment GainFromLoanPriorToRepayment	100000
CY2023Q2	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	75000.000
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	20300000
CY2022	rnlx	Fair Value Gain Related To Convertible Debt FairValueGainRelatedToConvertibleDebt	3900000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82210050
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72861448
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	976048
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82210050
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73837496
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10450114
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4554901

Files In Submission

Name	View Source	Status
0000950170-23-050231-index-headers.html	Edgar Link	pending
0000950170-23-050231-index.html	Edgar Link	pending
0000950170-23-050231.txt	Edgar Link	pending
0000950170-23-050231-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img76070624_0.jpg	Edgar Link	pending
img83584967_0.jpg	Edgar Link	pending
img83584967_1.jpg	Edgar Link	pending
img83584967_2.jpg	Edgar Link	pending
img83584967_3.jpg	Edgar Link	pending
img83584967_4.jpg	Edgar Link	pending
img83584967_5.jpg	Edgar Link	pending
img83584967_6.jpg	Edgar Link	pending
img83584967_7.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rnlx-20230630.htm	Edgar Link	pending
rnlx-20230630.xsd	Edgar Link	pending
rnlx-ex10_10.htm	Edgar Link	pending
rnlx-ex10_16.htm	Edgar Link	pending
rnlx-ex10_6.htm	Edgar Link	pending
rnlx-ex10_7.htm	Edgar Link	pending
rnlx-ex10_8.htm	Edgar Link	pending
rnlx-ex10_9.htm	Edgar Link	pending
rnlx-ex21_1.htm	Edgar Link	pending
rnlx-ex23_1.htm	Edgar Link	pending
rnlx-ex31_1.htm	Edgar Link	pending
rnlx-ex31_2.htm	Edgar Link	pending
rnlx-ex32_1.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rnlx-20230630_def.xml	Edgar Link	unprocessable
rnlx-20230630_lab.xml	Edgar Link	unprocessable
rnlx-20230630_cal.xml	Edgar Link	unprocessable
rnlx-20230630_pre.xml	Edgar Link	unprocessable
rnlx-20230630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNLXY
Renalytix plc Stock $rnlxy

2023 Q3 Form 10-K Financial Statement

#000095017023050231 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNLXY Renalytix plc Stock $rnlxy

2023 Q3 Form 10-K Financial Statement

#000095017023050231 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNLXY
Renalytix plc Stock $rnlxy